Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma
NCT02667574Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Nov 2014
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib in basal cell carcinoma (BCC), sponsored by CHU de Lille. Started Nov 2014; status: completed.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02667574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667574.